Tickers: XTSX:SVA, PINX:SEOVF, FRAA:PSH
LONDON, ONTARIO - TheNewswire - April 21, 2020 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today that it is implementing safety measures for its upcoming Annual Meeting of Shareholders ("AGM") to be held in Vancouver, BC on April 30, 2020, in response to public health authority guidelines issued concerning the COVID-19 pandemic.
Public health authorities across Canada continue to advise that both in-person contact and the congregation of groups be minimized in order to mitigate the risk of COVID-19 exposure or infection. Accordingly, shareholders are requested and strongly encouraged to vote electronically or by proxy on the matters before the meeting rather than attending the AGM in person. Voting instructions have been mailed to shareholders, and AGM related documents are accessible at www.sernova.com/investor/agm/. Immediately following the formal AGM, Sernova will host a conference call, and Dr. Philip Toleikis, President and CEO, will provide an update on Sernova's activities and respond to shareholder questions. Questions may be submitted to email@example.com prior to the call.
"The health and well-being of our shareholders, employees, collaborators, and communities, as well as preventing the spread of the COVID-19 virus is of utmost importance. We have been closely monitoring the COVID-19 situation and updating our company policies accordingly to make proactive adjustments and continue operations while doing our part to help 'flatten the curve.' We appreciate our shareholders' cooperation and understanding as the world navigates through these unprecedented times," said Dr. Philip Toleikis, President and CEO of Sernova Corp.
The conference call details for the Annual Meeting of Shareholders are set out below.
US Toll-Free: + 1-877-366-0711
Canada Toll-Free: + 1-866-627-1651
Int'l Toll-Free: + 1-302-709-8446
The conference participant passcode is 109 985 50. Following the conference call, a recording will be available at www.sernova.com/investor/agm
ABOUT SERNOVA'S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com
FOR FURTHER INFORMATION, PLEASE CONTACT:
Tel: (519) 858-5126
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Sernova's management on the date such statements were made, which include our beliefs about the effect on company operations of the COVID-19 virus and conduct and outcome of discussions, clinical programs, and our clinical trials. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Copyright (c) 2020 TheNewswire - All rights reserved.